Commercial RPS16 antibodies exhibit consistent performance across platforms, as demonstrated by these specifications from leading providers:
| Parameter | Proteintech (15603-1-AP) | Abcam (ab177951) | Abbexa (abx250022) | Boster Bio (A05230) |
|---|---|---|---|---|
| Host Species | Rabbit (Polyclonal) | Rabbit (Monoclonal) | Rabbit (Polyclonal) | Rabbit (Polyclonal) |
| Tested Applications | WB, IHC, IF/ICC, ELISA | WB, IP, IHC-P, ICC/IF | WB, IHC, IF/ICC, ELISA | WB |
| Dilution Range | WB: 1:500–1:1000 | WB: 1:1000 | WB: 1:500–1:2000 | WB: 1:500–1:2000 |
| Observed MW | 16 kDa | 16 kDa | 16 kDa | 16 kDa |
| Reactivity | Human, Mouse | Human, Mouse, Rat | Human, Mouse, Rat | Mouse |
| Key Citations | 3 publications | 3 publications | Not specified | Not specified |
RPS16 contributes to both ribosomal and non-ribosomal pathways:
Essential for rRNA processing and translational control via RNA binding .
Part of the small subunit (SSU) processome, critical for ribosome assembly .
HCC Progression: USP1 stabilizes RPS16 by removing K48-linked ubiquitination, promoting HCC cell proliferation and metastasis. Clinically, high USP1/RPS16 expression correlates with poor survival (HR = 2.34, p < 0.001) .
Prostate Cancer: RPS16 overexpression drives tumor growth via EMT (↓E-cadherin, ↑N-cadherin/Snail) and c-Myc stabilization .
Therapeutic Target: Knockdown of RPS16 in HepG2 cells induces G0/G1 arrest and apoptosis, confirming its pro-tumorigenic role .
RPS16 interacts with Epstein-Barr virus LMP1, enhancing its stability and promoting oncogenesis .
In plant models, RPS16 homologs inhibit viral replication by suppressing RNA silencing .
Diagnostic Use: IHC staining with RPS16 antibodies shows strong cytoplasmic positivity in breast carcinoma and neuronal tissues .
Functional Studies: siRNA-mediated RPS16 knockdown reduces HCC xenograft growth by 60% in murine models .
Biomarker Potential: Overexpression in prostate (AUC = 0.82) and gastric cancers (HR = 1.7, p = 0.003) highlights prognostic utility .